MitraClip™ Therapy: A Minimally Invasive Option
MitraClip™ transcatheter mitral valve repair (TMVr) is a minimally invasive treatment option for patients with significant mitral regurgitation (MR) who are considered unable to have surgery.1
Approximately 50% of symptomatic patients with severe MR are not candidates for surgery due to underlying factors.* MR patients who most need intervention are often the most likely to be denied surgery.2
*Based on a survey of severely symptomatic MR patients in NYHA Class III-IV (n = 396); 10% had surgery the following year.
The remainder had no surgery; medical management only.
Considerations for MitraClip candidates include1:
- Significant MR (MR ≥ 3+)
- Surgical risk factors including age, frailty, or severe comorbidities such as liver disease and pulmonary hypertension
MitraClip therapy is the only transcatheter mitral valve repair therapy recommended by the 2017 ESC/EACTS and 2016 ESC/HF Guidelines.3-4 Determining the severity of MR is an important factor in the management of the condition. The guidelines support aggressive monitoring and early action, with the goal of preventing complications due to LV volume overload.3
MAT-2011219 v1.0 | Item approved for Global OUS use only.
- MitraClip G4 Clip Delivery System Instructions for Use.
- Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358-1365.
- Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(36):2739-2791.
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.